



Health Technology Assessment Review Implementation Advisory Group

Webinar - Frequently Asked Questions

Will the IAG provide advice on all 50 Recommendations?

The IAG has been asked to provide advice on the prioritisation of all 50 of the HTA Review recommendations. Government has not accepted or rejected the implementation of any recommendation.

Is the IAG considering alternative reform options?

Presenting alternative reform options beyond the scope of the HTA review recommendations is not within the scope of the IAG's roles. However, where a recommendation may be implemented in several ways the IAG is considering these options and taking into consideration movement in the sector which has occurred since the Review's publication in developing its advice to government. This consideration will inform the IAG's advice on sequencing and prioritisation of implementation actions.

What the anticipated patient and system benefits and outcomes from implementation of these initiatives?

The IAG anticipates that its advice on an implementation roadmap for government consideration will provide further insights into the anticipated benefits of individual initiatives. The Chair anticipates that one key measure of success for the IAG's work will be if, by creating a more flexible system that proactively addresses issues earlier, a reduction in the number of re-submissions required to achieve a positive recommendation is achieved.

Is the IAG considering how implementation of the HTA Review's recommendations would fit with other reform processes underway?

Identifying alignment and efficiencies between the IAG's Roadmap and other initiatives has been a major focus of the IAG's work.

The IAG has been proactive in attempting to identify links with work already underway throughout its processes. This has included undertaking additional consultations with stakeholders from across the sector, who have helped identify other work and linkages which will inform the IAG's advice.

Will the approach to joint performance metrics proposed by the IAG consider MSAC processes as well as PBAC processes.

The jointly owned performance targets recommendation of the HTA review largely focussed on the processes and mechanisms associated with the PBS & medicines. This work builds upon the Strategic Agreement between the Department and Medicines Australia, which provides an extensive program of associated performance metric work. However, the IAG has been working to understand the potential implications of reform implementation beyond

medicines, and how these might be monitored and reported to ensure that this is captured in its advice to government.

What is the deadline for providing further feedback through the survey to be sent to webinar attendees?

The survey will be open until 17 October 2025.

You can find more information about the IAG's work [here](#).